Our Latest News - BUHLMANN

BUHLMANN News

Visit BUHLMANN at DDW 2017- Booth 1925

Digestive Diseases Week (DDW) 2017 BUHLMANN Diagnostics Corp  Booth: #1925 May 06 - 09, 2017 | McCormick Place | Chicago, IL Learn More Click & Contact DDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! Collin Shaw, VP of Business Development Jennifer Stuart, Technical
Continue Reading

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that three of its novel products, Quantum Blue® Infliximab Assay, IBDoc® and CALEX®Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada. Quantum Blue® Infliximab® and CALEX® CAP devices were approved as Class 2 medical devices
Continue Reading

BUHLMANN Highlights: GanglioCombi MAG ELISA

BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100476 DOWNLOAD WHITE PAPER BÜHLMANN GanglioCombi® MAG ELISA Comprehensive assay for anti-MAG and most prevalent anti-Ganglioside antibodies: (GM1, GM2, GD1a, GD1b, and GQ1b). The Neuroimmunology product line by BÜHLMANN is a list of robust assays for simple, esoteric
Continue Reading

The Value of Calprotectin in Inflammatory Bowel Disease Management

Calprotectin: The Key to a Successful Treatment Pathway for IBD What is Inflammatory Bowel Disease? Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as  can be seen in many chronic diseases. IBD includes several different diseases; the two most
Continue Reading

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading

BUHLMANN LabSense News: Winter 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the second edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News.  Here you will also be able to access valuable resources, applications, and other newsworthy items specific to fields of in vitro diagnostics and scientific research. In this edition we
Continue Reading

Quantum Blue® Infliximab Assay Highlights

US: BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US. Not to be used in diagnostic procedures. Canada: BÜHLMANN Quantum Blue® Infliximab: Health Canada License: 98838 Rapid, Simple, Accurate Quantitative Results BÜHLMANN’s Quantum Blue® Product line is designed with an innovative solution based on established lateral flow technology which utilizes highly specific monoclonal antibodies to capture
Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2017

Canadian Digestive Diseases Week (CDDW) 2017 BUHLMANN Diagnostics Corp Booth: #1032 Mar 03 – 06, 2017 LOCATION The Fairmont Banff Springs Banff, Alberta LEARN MORE Click & Contact CDDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! COLLIN SHAW VP of Business Development
Continue Reading

Higher sensitivity detecting anti-myelin-associatedglycoprotein (MAG) IgM autoantibody using antigen purified from human brain

BÜHLMANN Anti-MAG Autoantibodies ELISA: Jaskowski et al. Higher sensitivity detecting anti-myelin-associatedglycoprotein (MAG) IgM autoantibody using antigen purified from human brain. 8th International Congress of Neuroimmunology. October 15-19, 2006.  Nagoya, Japan. Highlights from this Publication "The MAG EIA showed excellent sensitivity (97.5%) when compared to Western blot and has the advantages of being objective...and identifying [subjects] that
Continue Reading

Basophil Activation Testing – Standardized

3 Reasons to Consider this Method in Kinase Inhibitor Drug Development Basophils are the circulating immune cells that participate in allergic reactions and share many of the signaling pathways that are also present in other types of immune cells that may develop into blood cancers or participate in the development of autoimmune disorders.  Therefore, measuring
Continue Reading